All News

Patients with a disorder from this family of neurodevelopmental conditions face a lack of approved treatment options, making radiprodil poised to transform the treatment paradigm.

Ononogbu discusses research, health equity, and sickle cell advancements.

Approximately 74% of patients with chronic rhinosinusitis with nasal polyps receiving depemokimab across 2 trials did not need additional intervention.

Appellate court addresses application of legal doctrine to the matter.

Treatment with HTD1801 resulted in significant reductions in the hemoglobin A1c level and improved key cardiometabolic and liver parameters.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

As indicated by prior literature, a second dose of intravenous immunoglobulin (IVIG) in patients with Guillain-Barré syndrome increases serum immunoglobulin G levels without improving clinical outcomes.

Patients with chronic hepatitis B (CHB) who received the Hecolin hepatitis E virus (HEV) 3-dose regimen had a somewhat low incidence of local and systemic adverse events.

Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.

Data privacy and security breaches are a critical concern with AI in health care.

The treatment is indicated for patients aged 6 and older with hypertension, the reduction of stroke in hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.

Sharita Howe, PharmD, discusses her recent acknowledgement by MM+M, who acknowledged her as a part of the next wave of health care leaders in their recognition of 40 under 40 leaders in health care.

Pharmacists can optimize management of this condition with intravenous iron therapy guidance.

A phase 2 study showed that elotuzumab combined with pomalidomide, bortezomib, and dexamethasone was safe and efficacious.

The 3CL protease inhibitor is designed to suppress the replication of SARS-CoV-2, preventing COVID-19 illness, even if a household member is infected.

The patient is the first to be cured using lovotibeglogene autotemcel, a novel cell-based gene therapy.

In this retrospective study, investigators evaluated a pharmacy-led initiative in the emergency department (ED), finding a potential reduction in ED revisits and hospital readmissions, though results were not statistically significant.

The new indication would include adults with heart failure with a left ventricular ejection fraction (LVEF) of 40% or higher, such as mildly reduced or preserved LVEF.

Although dietary changes have historically been a key approach to managing eosinophilic esophagitis, their limitations highlight the need for pharmacologic treatments.

Although RSV has long been associated with infants and young children, research demonstrates that it is also a significant health risk for adults over the age of 60.

Pharmacists can identify medications and conditions that may augment or exacerbate constipation.

Data from conference abstracts and presentations indicate that both preexposure prophylaxis methods continue to demonstrate efficacy.

Treatment with ruxolitinib in patients with myelofibrosis and anemia was associated with more inpatient medical center and emergency department visits while increasing health care-related financial burdens compared with nonanemic patients.

David S. Bateshansky, PharmD, BCOP, discusses his role as an oncology pharmacist at USC Norris Comprehensive Cancer Center, noting the evolving recognition of pharmacists' contributions on cancer care teams.

Tarlatamab was approved by the FDA in May 2024 for patients who progressed after platinum-based chemotherapy.

This marks steps toward improving health care pricing transparency, but further reforms are needed to reduce costs long-term.

Alcohol consumption, though typically associated with adverse health outcomes, could be associated with reduced low-density lipoprotein cholesterol (LDL-C) and improved high-density lipoprotein cholesterol (HDL-C).